Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis

Hepatology Research

Volumn 16, Issue 1, 1999, Pages 12-18

  Iwasaki, Shinji ^a   Tsuda, Keisuke ^a   Ueta, Hiroshi ^a   Aono, Rei ^a   Ono, Masafumi ^a   Saibara, Toshiji ^a   Maeda, Takashi ^a   Onishi, Saburo ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Bezafibrate; mdr2; MDR3; P glycoprotein; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; BEZAFIBRATE; GLYCOPROTEIN P; IMMUNOGLOBULIN M; MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CHOLESTASIS; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; ORAL DRUG ADMINISTRATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS;

EID: 0032750057     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(99)00033-9     Document Type: Article

References (9)

1. Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22:759-66.
2. Day A.P., Feher M.D., Chopra R., Mayne P.D. The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism. 42:1993;839-842.
3. Chianale J., Vollrath V., Wielandt A.M., Amigo L., Rigotti A., Nervi F. et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem. J. 314:1996;781-786.
4. Fukuo Y., Kitami T., Nomoto T., Terashi A. A lipid lowering drug (bezafibrate) has a favorable effect on liverenzymes (Al-P and γ-GTP). J. Nippon. Med. School. 63:1996;424-430.
5. Puglielli L., Amigo L., Arrese M., Nunez L., Rigotti A., Garrido J. et al. Protective role of biliary cholesterol and phospholipid lamellae against bile acid-incuded cell damage. Gastroenterology. 107:1994;244-254.
6. Smit J.J., Schinkel A.H., Oude Elferink R.P., Groen A.K., Wagenaar E., van Deemter L. et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 75:1993;451-462.
7. de Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998; 95:282-287.
8. Smith A.J., de Vree J.M., Ottenhoff R., Oude Elferink R.P., Schinkel A.H., Borst P. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (-/-) mice. Hepatology. 28:1998;530-536.
9. Piquette-Miller M., Pak A., Kim H., Anari R., Shahzamani A. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm. Res. 15:1998;706-711.